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Degradation of cytosolic proteins depends largely on
the proteasome, and a fraction of the cleavage products
are presented as major histocompatibility complex
(MHC) class I-bound ligands at the cell surface of anti-
gen presenting cells. Proteolytic pathways accessory to
the proteasome contribute to protein turnover, and
their up-regulation may complement the proteasome
when proteasomal proteolysis is impaired. Here we
show that reduced reliance on proteasomal proteolysis
allowed a reduced efficiency of MHC class I ligand pro-
duction, whereas protein turnover and cellular prolifer-
ation were maintained. Using the proteasomal inhibitor
adamantane-acetyl-(6-aminohexanoyl)3-(leucinyl)3-
vinyl-(methyl)-sulphone, we show that covalent inhibi-
tion of all three types of proteasomal -subunits (1, 2,
and 5) was compatible with continued growth in cells
that up-regulate accessory proteolytic pathways, which
include cytosolic proteases as well as deubiquitinating
enzymes. However, under these conditions, we observed
poor assembly of H-2Db molecules and inhibited presen-
tation of endogenous tumor antigens. Thus, the tight
link between protein turnover and production of MHC
class I ligands can be broken by enforcing the substitu-
tion of the proteasome with alternative proteolytic
pathways.
Several cytosolic proteases, including the 26 S proteasome,
bleomycin hydrolase, puromycin-sensitive amino peptidase
and leucine-aminopeptidase, contribute to the generation of
MHC1 class I ligands (1–3). However, the 26 S proteasome, a
large multicatalytic proteinase complex, carries out the bulk of
both cytosolic protein degradation and MHC class I ligand
production (1, 2). This protease has a multisubunit 20 S core
structure containing two sets of three distinct catalytic sites, X
(5), Y (1), and Z (2), associated with one or two 19 S regu-
latory accessory complexes (1, 2). The proteasome generates a
wide range of peptide cleavage products (3–24 amino acids in
length) that are ultimately degraded into free amino acids
(4–6). In mammalian cells, a minor subset of peptides is res-
cued from further degradation and is translocated from the
cytosol into the endoplasmic reticulum for assembly with MHC
class I molecules. The MHC class I pathway is thereby assured
constitutive production of ligands through cytosolic proteolysis.
In the case of an immunological challenge, mammalian cells
express IFN--inducible proteasomal -subunits (LMP7/5i,
LMP2/1i, and MECL-1/2i) that replace the constitutively ex-
pressed subunits in newly synthesized proteasomes (1). Such
replacement leads to increased proteasomal production of pep-
tides with hydrophobic C termini, usually preferred for both
TAP transport and MHC class I binding (7). However, the
majority of potential MHC class I ligands, as deduced from
their primary structure, are not efficiently processed, although
the correct motifs for TAP transport and MHC class I binding
are contained in the protein sequence (8, 9). Such failure may
depend on proteolysis by cytosolic proteases inefficient at gen-
erating the requisite cleavage products. Thus, it is possible that
MHC class I processing may be regulated by differential par-
ticipation of non-proteasomal peptidases in cytosolic protein
degradation. Impaired proteasomal activity can be functionally
compensated, at least in part, by another large cytosolic pepti-
dase, tripeptidyl-peptidase II (10–13). Despite covalent inhibi-
tion by NLVS (14) or lactacystin (15), EL-4 lymphoma cells
adapted to growth in the presence of this inhibitor (denoted
EL-4ad) maintain cytosolic proteolysis and cell viability by a
mechanism that includes compensatory up-regulation of trip-
eptidyl-peptidase II (10–12). However, it is unknown whether
the adapted state has functional consequences at the level of
MHC class I ligand generation and antigen presentation to
CTLs.
We show that lymphoma cells with reduced reliance on pro-
teasomal activity no longer efficiently produced MHC class I
ligands, although cytosolic proteolysis continued, and prolifer-
ation was not altered compared with control cells. Assembly of
H-2Db molecules was dramatically reduced, and endogenous
tumor antigens were not presented efficiently under these con-
ditions. This phenotype contributed to escape from tumor re-
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jection in tumor graft experiments in syngeneic C57Bl/6 mice.
Using a GFP reporter to measure proteolysis, we show in live
cells that non-proteasomal serine peptidase activity partici-
pated in protein degradation, but inhibition of these enzymes
failed to have a significant effect on the assembly of H-2Kb
molecules. Continued proteolysis in proteasome-impaired cells
afforded the cell the requisite housekeeping functions while
preventing the full display of the usual set of MHC class I-re-
stricted epitopes.
MATERIALS AND METHODS
Cells and Transfections—EL-4 is a benzopyrene-induced thymoma
cell line of the H-2b haplotype, derived from C57Bl/6 mice. RMA is a
Rauscher’s virus-induced T cell lymphoma cell line and is also derived
from C57Bl/6. Adaptation to the proteasomal inhibitor NLVS was ob-
tained by incubation of these cells in RPMI 1640 medium containing 5%
fetal calf serum, 1% penicillin/streptomycin, 1% glutamine, and 10 M
NLVS. Gradually outgrowing cells were selected and cultured in 50 M
NLVS over a period of several weeks as described previously (10).
EL-4.Ub-R-GFP and EL-4.Ub-M-GFP cells were obtained by electropo-
ration of EL-4 cells with constructs Ub-R-GFP and Ub-M-GFP (16),
respectively, and stable clones were selected with 0.5 mg/ml G418.
Electroporation was preformed in a Bio-Rad Gene-Pulser at 250 V and
960 microfarads.
Proteasomal Inhibitors—NLVS (14) covalently modifies all catalyti-
cally active subunits of the proteasome, but with preference for the
-subunits with chymotryptic specificity. Several derivatives of NLVS
were obtained by variations in the peptide scaffold: 4-hydroxy-5-iodo-
3-nitrophenylacetyl-Ala-Ala-Phe-vinyl sulfone (AAF-VS) and 4-hy-
droxy-5-iodo-3-nitrophenylacetyl-Leu-Leu-Gly(cis)-vinyl sulfone (LLG-
(cis)-VS). LLG-VS was obtained in the cis- and trans-isomers due to the
absence of a side chain on the P1 glycine. Whereas the trans-form of
LLG-VS modifies proteasomal -subunits, the cis-form modifies yet
uncharacterized targets in the cytosol distinct from the proteasome.
Adamantane-acetyl-(6-aminohexanoyl)3-(leucinyl)3-vinyl-(methyl)-
sulphone (Ada-Ahx3-Leu3-VS) is an N-terminally extended vinyl sul-
fone inhibitor that blocks all proteasomal -subunits in a covalent
manner (17).
Peptide Substrates and Peptidase Assays—To assay the activity of
the proteasome, we used the fluorogenic substrates succinyl-LLVY-
AMC, benzyloxycarbonyl-GGL-AMC, t-butyloxycarbonyl-LRR-AMC,
and benzyloxycarbonyl-YVAD-AMC (Sigma). To assay tripeptidyl-pep-
tidase II activity, we used AAF-AMC (Sigma). Cell extracts or protea-
some-enriched fractions and substrate (100 M) were mixed in 50 mM
Tris (pH 7.5), 5 mM MgCl2, 1 mM dithiothreitol, and 2 mM ATP in a final
volume of 100 l. Peptide hydrolysis was monitored by fluorescence
spectroscopy (PerSeptive Biosystems, Framingham, CT) with excitation
at 380 nm and fluorescence reading at 460 nm.
Proteasome Purifications—Preparation of proteasome-enriched frac-
tions was performed using 0.5–1 109 control or adapted EL-4 cells and
C57Bl/6 livers. Cells were washed with phosphate-buffered saline and
lysed by vortexing with glass beads in 50 mM Tris base (pH 7.5), 250 mM
sucrose, 5 mM MgCl2, 1 mM dithiothreitol, and 2 mM ATP. Glass beads
and cell debris were removed by sequential centrifugations at 3000 and
14,000 rpm, respectively. Microsomes were removed by centrifugation
for 1 h at 100,000  g, and large cytosolic proteins or protein complexes
containing proteasomes and tripeptidyl-peptidase II were then sedi-
mented at 100,000  g for 5 h. The resulting pellet was dissolved in 50
mM Tris base (pH 7.5), 5 mM MgCl2, 1 mM dithiothreitol, 2 mM ATP, and
30% glycerol.
Pulse-Chase Experiments—Cells were starved in methionine/cys-
teine-deficient medium for 45–60 min, pulsed with [35S]methionine for
15 min, and chased for the indicated times. Cells were collected by
centrifugation and lysed in 0.5% Nonidet P-40 lysis buffer, and MHC
class I molecules were immunoprecipitated with rabbit anti-p8 serum
FIG. 1. Impaired assembly of MHC class I molecules in cells with reduced reliance on proteasomal activity. a, pulse-chase
experiments were performed on control EL-4 cells, EL-4 cells treated with 50 M NLVS for 16 h, or EL-4ad cells. H-2Db molecules were
immunoprecipitated (IP) with anti-H-2Db antibody B22.249.1 in the presence or absence of an H-2Db-binding peptide, followed by SDS-PAGE
analysis and autoradiography. b, RMA cells left untreated or treated with 50 M NLVS for 3 h (3h), adapted (ad) to 50 M NLVS (RMAad), or
adapted to NLVS and washed (wash) and RMA-S cells were subjected to pulse-chase experiments. H-2Db molecules were immunoprecipitated in
the presence or absence of an H-2Db-binding peptide, followed by SDS-PAGE analysis and autoradiography. Glycosylated heavy chains (GHC) that
were transported from the endoplasmic reticulum, heavy chains (HC), and 2-microglobulin (2m) are indicated with arrows.
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(H-2Kb cytoplasmic tail), monoclonal antibody Y3 (H-2Kb 12), or an-
tibody B22.249.1 (H-2Db 12) as described previously (18). Viral pep-
tide epitopes are known to stabilize the MHC class I complex at 4 °C.
We added Db-binding peptide ASNENMDAM (influenza NT60, amino
acids 366–374) at 10 M to detect the presence of unfolded heavy
chains. Immune complexes were removed by adsorption to staphylococ-
cus A and analyzed by SDS-PAGE as previously described (10).
Generation of CTLs and 51Cr Release Assays—For the generation of
CTLs specific for tumor antigens expressed by EL-4 cells, we primed B6
mice two to three times with control or adapted EL-4 cells transfected
with B7.1. Priming of responses with EL-4 cells not expressing B7.1 led
to very low CTL responses or no response at all. To generate RMA
cell-specific CTLs, we primed C57BL/6 mice with irradiated RMA cells
two to three times; and for the subsequent generation of in vitro effector
cells, 25  106 splenocytes were restimulated in vitro with 1–2  106
irradiated tumor cells for 5 days. The H-2Db restricted CTL clone ln17
was acquired from Elisabeth Wolpert and Vanoohi Fredriksson (MTC,
Karolinska Institutet). The conditions for generation and analysis of
this CTL have been described previously (23).
Tumor Growth Experiments—Control EL-4 and EL-4ad cells (cul-
tured in RPMI medium 1640 supplemented with 5% fetal calf serum)
were washed with phosphate-buffered saline and resuspended in 200
l/inoculate. The cells were inoculated into the right flanks of syngeneic
C57Bl/6 mice at 104 or 106 cells/animal. Some of the mice were irradi-
ated with 400 rads prior to tumor inoculation to inhibit antitumor
immune responses. Outgrowth of the tumors was monitored by palpa-
tions weekly.
RESULTS
Tumor Cells with Reduced Reliance on Proteasomal Proteol-
ysis Fail to Efficiently Produce MHC Class I Ligands—EL-4
cells can adapt to proliferate in the presence of high concentra-
tions of NLVS, a covalent proteasomal inhibitor (denoted EL-
4ad cells) (10). MHC class I molecules show allelic variation in
their ability to undergo assembly and transport during protea-
somal inhibition, and H-2Db is one allele that fails to assemble
in cells that are treated with proteasomal inhibitors for short-
term periods (19–21). We therefore investigated H-2Db ligand
production in EL-4ad cells, which proliferate with low protea-
somal activity. In control EL-4 cells, almost all folded H-2Db
molecules were transported from the endoplasmic reticulum
within 120 min after onset of the chase, as judged from their
acquisition of Golgi-specific glycan modifications (Fig. 1a, left
panel). In EL-4 cells treated with NLVS (50 M, 3 h), only a
minimal fraction of H-2Db heavy chains were transported even
after long chase times (Fig. 1a, middle panel), as reported
previously (21). Stabilization of H-2Db molecules in cell lysates
of NLVS-treated EL-4 cells by addition of the influenza
nucleoprotein-(366–374) peptide confirmed that most of these
H-2Db heavy chains were devoid of peptide ligand ( lanes)
(22). In EL-4ad cells, a fraction of H-2Db resumed folding,
although at much lower levels compared with control EL-4
cells. The majority of H-2Db heavy chains in EL-4ad cells
remained unassembled in the endoplasmic reticulum devoid of
peptide, as indicated by the stabilizing effect of nucleoprotein-
(366–374) added to lysates of these cells (Fig. 1a, right panel).
In RMAad cells, which were similarly adapted to NLVS, mat-
uration of H-2Db molecules was comparable to that observed in
EL-4ad cell (Fig. 1b). Despite normal proliferation, tumor cells
can therefore avoid production of most H-2Db ligands by re-
duced reliance on proteasomal activity.
Tumor cells often acquire deficiencies in MHC class I antigen
presentation to escape from host immune detection. To test
whether reduced reliance on proteasomal activity has func-
tional consequences, we tested presentation of endogenous tu-
mor antigens to CTLs by EL-4ad and RMAad cells. Both EL-4
and RMA cells express H-2Kb-restricted (gagL75–83) as well as
H-2Db-restricted (env189–196) murine leukemia virus-derived
peptides and, in addition, an endogenous H-2Db-restricted tu-
mor epitope (23). We generated antitumor CTLs by priming
C57Bl/6 mice and subsequent in vitro restimulation of spleno-
cytes with B7.1-transfected EL-4 cells. We found that tumor
antigen-specific CTLs performed efficient killing of control
EL-4 cells, whereas EL-4ad cells were not efficiently recog-
nized, although the latter were killed significantly better than
FIG. 2. Decreased tumor antigen
presentation due to reduced reliance
on proteasomal activity. 51Cr release
assays were performed using antitumor-
specific CTLs tested against 51Cr-labeled
EL-4 (a) and RMA (b) target cells. RMA-S
and C4.4–25 are MHC class I mutant
cell lines used to control for nonspecific
target cell killing. Tumor antigen (NK-
GENAQAI30)-specific CTL clone ln17 was
used to test antigen presentation by
RMA, RMA-S, and RMAad cells (c). Anti-
gen recognition was quantified by detec-
tion of IFN- secretion by effector cells, as
described previously (31). Bulk protein
turnover was assessed by metabolic label-
ing of control EL-4 and EL-4ad cells with
35S for 15 min, and the fate of radiola-
beled proteins was followed by a chase for
the indicated times, SDS-PAGE separa-
tion, and autoradiography (d). 2m/,
2-microglobulin-deficient; E/T, effector
to target ratio.
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C4.4-25, a 2-microglobulin-deficient variant of EL-4 (Fig. 2a
and data not shown). We also found that RMAad cells likewise
had a reduced ability to present endogenous tumor antigens
compared with control RMA cells. Although RMAad target cells
were killed at higher levels than TAP-deficient RMA-S cells,
5–10 times more CTLs were required to obtain the same degree
of killing as seen on RMA target cells (Fig. 2b). Even more
pronounced differences were obtained using CTL clone ln17,
specific for tumor antigen-specific peptide NKGENAQAI re-
stricted by H-2Db (20). In line with previous data, we found
that ln17 detected the presence of the tumor-specific epitope on
RMA cells, but failed to recognize RMA-S cells (Fig. 2c). Fur-
thermore, no recognition of RMAad cells was observed. MHC
class I-restricted presentation of a tumor antigen-specific pep-
tide can thereby be inhibited when proteasomal proteolysis is
inhibited in a suitable manner. Because we used IFN- secre-
tion as readout for antigen detection by ln17, these data also
exclude that the differences in CTL killing were due merely to
differences in target cell apoptosis when comparing control and
NLVS-adapted target cells. These data support the conclusion
that EL-4ad cells fail to display the full repertoire of MHC class
I-associated antigens at the cell surface.
The chymotrypsin-like activity of the proteasome is required
for the production of most MHC class I ligands and is normally
rate-limiting for intracellular proteolysis (1, 4, 7). To visualize
protein turnover in EL-4ad cells, we performed pulse-chase
experiments with [35S]methionine and displayed labeled pro-
tein by SDS-PAGE. As expected from the proliferation rates of
these cell lines (10), we observed a similar rate of decay of
labeled proteins when comparing control EL-4 and EL-4ad cells
(Fig. 2d). We conclude that NLVS-adapted cells have a severely
inhibited chymotryptic proteasomal activity, as deduced from
experiments employing active site-directed covalent probes.
When complemented by the induction of other cytosolic pro-
teases (10–12), the remaining proteasomal activity is adequate
for normal protein turnover, but not for production of all class
I ligands.
Up-regulation of Deubiquitinating Enzymes and Non-protea-
somal Peptidases in EL-4ad Cells—The activity of the ubiq-
uitin-specific protease USP14 is associated with the 19 S cap
proteasome and is up-regulated when the proteasome is inhib-
ited (24). More generally, inhibition of proteasomal proteolysis
should lead to accumulation of ubiquitin-conjugated sub-
strates. Adaptation to proteasomal inhibitors might well in-
clude increased activity of deubiquitinating enzymes to deal
with such accumulation. We therefore examined whether this
was the case also in EL-4ad cells using 125I-labeled ubiquitin-
vinyl sulfone (24). Cellular fractions of control EL-4 and EL-
4ad cells (cytosolic as well as proteasome-enriched fractions)
were incubated with ubiquitin-vinyl sulfone, and covalently
modified polypeptides were separated by SDS-PAGE. We found
increased labeling of IsoT1, USP14, and UCH-L1 in EL-4ad
cells compared with control EL-4 cells (Fig. 3a), in line with
what was observed in acutely treated EL-4 cells (24). More
FIG. 3. Proteolysis accessory to the
proteasome analyzed by covalent vi-
nyl sulfone probes. a, isopeptidase ac-
tivities were analyzed using ubiquitin-vi-
nyl sulfone (UbVS) in cellular fractions
from control EL-4 and EL-4ad (Ad) cells.
1hr pel and 5hr pel, protein pellets cre-
ated by centrifugation at 100,000 g for 1
and 5 h, respectively. This procedure sed-
iments high molecular mass proteins or
protein complexes. b and c, different ra-
diolabeled peptide vinyl sulfones ([125I]N-
LVS, [125I]LLG-VS, and [125I]AAF-VS) ex-
hibiting different specificities were
incubated with cell lysates prepared from
untreated (), NLVS-treated (2 h; 2h), or
NLVS-adapted (ad) lymphoma cell lines.
Lysates prepared from EL-4 (b) and RMA
(c) cells were separated by SDS-PAGE
and analyzed by autoradiography.
Whereas the first and third compounds
efficiently labeled the 5- and 5i-subunits
of the proteasome, [125I]LLG-VS labeled
other yet uncharacterized cellular
proteases.
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active ubiquitin removal could prepare these substrates for
degradation by other proteases.
Two additional active-site probes with different peptide scaf-
folds were used (25), [125I]AAF-VS and [125I]LLG-VS, to exam-
ine whether residual proteasomal activity is mediated by the
5/5i-subunits (X/LMP7). None of these probes labeled 5/5i-
subunits (X/LMP7) in lysates of EL-4ad cells, whereas strong
labeling was detected in lysates of control EL-4 cells (Fig. 3b).
This confirms that virtually no catalytic activity remains for
the 5/5i-subunits (X/LMP7) in EL-4ad cells, which is impor-
tant in view of the fact that small amounts of peptide ligand
suffice to load MHC class I molecules with peptide (26). Inter-
estingly, using [125I]LLG(cis)-VS, we detected a series of mod-
ified polypeptides distinct from proteasomal -subunits. Be-
cause vinyl sulfones are mechanism-based probes (14, 27), we
conclude that these polypeptides correspond to additional, yet
to be identified, proteases. This activity is not inhibited by
NLVS, further supporting the alteration in proteolytic specific-
ity in EL-4ad cells (Fig. 3b, middle panel). Labeling of the
5/5i- subunits (X/LMP7) with [
125I]NLVS was likewise inhib-
ited in RMAad cells when tested with these peptide vinyl
sulfones (Fig. 3c).
Proteolysis Accessory to the Proteasome Supports Protein
Degradation, but Is Relatively Ineffective in MHC Class I Li-
gand Production—We next made stable EL-4 transfectants
expressing Ub-R-GFP to monitor proteasomal degradation of a
protein substrate in live cells (16). GFP was converted into an
N-end rule substrate and was degraded in EL-4 cells due to its
FIG. 4. Measuring proteasomal degradation by fluorescent ubiquitinated substrates in live cells. Shown are the results from FACS
analysis of EL-4 cells stably transfected with Ub-M-GFP (a) or Ub-R-GFP (b and c). EL-4.Ub-R-GFP cells were left untreated (b) or were treated
with 10 M NLVS (c). The level of proteasomal activity in EL-4.Ub-R-GFP cells treated with 10 M NLVS was measured by cytosolic high molecular
mass protein (100,000  g, 5 h) cleavage of the fluorogenic peptide substrates succinyl (succ)-LLVY-AMC, t-butyloxycarbonyl(boc)-LRR-AMC, and
benzyloxycarbonyl (z)-YVAD-AMC (d). Also shown are the results from FACS analysis of EL-4.Ub-R-GFP cells treated with up to 50 M NLVS
(e–h).
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N-terminal arginine, whereas Ub-M-GFP was comparatively
stable (Fig. 4, a–c) because of the presence of a methionine
residue. NLVS treatment of EL-4.Ub-R-GFP cells led to accu-
mulation of fluorescence, as detected by FACS. In line with
data from yeast mutants (28, 29), efficient inhibition of primar-
ily the chymotryptic proteasomal activity was sufficient for
accumulation of fluorescence (Fig. 4, c and d). In addition, the
accumulation of R-GFP fluorescence observed in cells exposed
to 10 M NLVS also correlated with the induction of cellular
toxicity and subsequent cell death (data not shown). These data
further confirm that NLVS is indeed an efficient inhibitor of
proteasomal protein degradation in live cells.
We next tested whether inhibition of accessory pathways has
any effect on cytosolic proteolysis. To do this, we accumulated
high levels of the R-GFP substrate in live EL-4.Ub-R-GFP cells
and then blocked protein synthesis to study changes in the
steady state of the substrate (Fig. 5, a–d). This revealed resid-
ual substrate degradation in the continued presence of 10 M
NLVS because a substantial fraction of the substrate was re-
moved after 8 h. However, this was inhibited by treatment with
AAF-CMK, an efficient inhibitor of tripeptidyl-peptidase II and
other serine oligopeptidases (Fig. 5, c and d). Although inhibi-
tion of oligopeptidases by AAF-CMK had minor effects on un-
treated EL-4.Ub-R-GFP cells, we observed a significant effect
FIG. 5. Degradation of an N-end rule substrate is influenced by non-proteasomal oligopeptidases. Shown are the results from FACS
analysis of EL-4.Ub-R-GFP cells incubated with 10 M NLVS for 16 h (a) and further incubated for 8 h in the presence of no addition (b),
cycloheximide (c), or 10 M AAF-CMK (d). EL-4.Ub-R-GFP cells were incubated in the presence of NLVS (0, 2, 5, or 10 M) in combination with
AAF-CMK (0, 5, or 10 M) (e). Control EL-4 and EL-4ad cells were pulsed with [35S]methionine, and transport of H-2Kb molecules was followed
by immunoprecipitation and SDS-PAGE in the presence () or absence () of 50 M NLVS and 10 M AAF-CMK (f). The cells were incubated with
the protease inhibitors for 3 h prior to metabolic labeling. GHC, glycosylated heavy chains; HC, heavy chains; 2m, 2-microglobulin.
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on R-GFP accumulation upon treating EL-4.Ub-R-GFP cells
with both NLVS and AAF-CMK in combination (Fig. 5e). These
data show that non-proteasomal oligopeptidase activity indeed
contributes to cytosolic proteolysis, especially during situations
of limiting or insufficient proteasomal activity.
To further study whether oligopeptidases inhibitable by
AAF-CMK are important in generating MHC class I ligands,
we performed a pulse-chase experiment with [35S]methionine
metabolic labeling and precipitation of H-2Kb molecules. A
substantial fraction of H-2Kb molecules continue to assemble in
EL-4ad cells (10). We examined whether this may be due to
ligands produced by oligopeptidases inhibitable by AAF-CMK.
We found that this treatment had minor effects on the assem-
bly and transport of H-2Kb molecules in EL-4ad cells and also
in control EL-4 cells with active proteasomes (Fig. 5f). We
conclude that pathways accessory to proteasomal proteolysis
that are inhibited by AAF-CMK support protein degradation,
but reveal poor yields of MHC class I ligands.
Evidence for Continued Cell Survival and Growth without
Significant Proteasomal Activity—EL-4ad cells continue to de-
pend on proteasomal -subunit activity, at least to some extent
(30). NLVS fails to block 2- and 2i-subunits (Z/MECL-1) in
vivo, a pattern of inhibition that is shared between NLVS and
other covalent proteasomal inhibitors such as lactacystin (15)
and epoxomicin (31). To examine if residual proteasomal activ-
ity influences the viability of EL-4ad cells, we used Ada-Ahx3-
Leu3-VS, a cell-permeable tripeptide vinyl sulfone that co-
valently modifies all proteasomal -subunits with comparable
efficiency (17). We found that proteasome-enriched fractions
from control EL-4 or EL-4ad cells treated with either NLVS or
Ada-Ahx3-Leu3-VS had almost completely blocked chymotryp-
tic and trypsin-like proteasomal activities, whereas the
caspase-like activity was 70% inhibited (Fig. 6a). Initially, at
early time points, we observed an induction of the trypsin- and
caspase-like specificities during inhibitor treatment, possibly
due to allosteric effects on the proteasome upon binding of the
inhibitor to the X/LMP7 site (32). Consistent with the enzyme
assays using fluorogenic peptide substrates, labeling of -sub-
units with Ada-[125I-Tyr]Ahx3-Leu3-VS in cell lysates followed
by separation of the -subunits by SDS-PAGE confirmed that
all proteasomal active sites were covalently modified during
treatment of live cells with the Ada-Ahx3-Leu3-VS inhibitor
(Fig. 6a, lower panel). Furthermore, EL-4ad cells proliferated
regardless of the presence of Ada-Ahx3-Leu3-VS, whereas con-
trol EL-4 cells died within 48 h (Fig. 6b). To confirm that
proteasomes of proliferating EL-4ad cells were indeed modi-
fied, we prepared proteasome-enriched fractions from cells
treated for several days with Ada-Ahx3-Leu3-VS. This analysis
revealed results similar to those observed in acutely treated
cells. Essentially no residual tryptic and chymotryptic activi-
ties and inhibited caspase-like activity were detected (data not
FIG. 6. EL-4ad cell proliferation despite inhibition of all cata-
lytic sites of the proteasome by Ada-Ahx3-Leu3-VS. a, control EL-4
or EL-4ad cells were incubated with either 50 M NLVS or 50 M
Ada-Ahx3-Leu3-VS for the indicated times, and cell lysates were sub-
mitted to differential centrifugation for partial purification of protea-
somes. The samples were either tested for cleavage of the peptide
reporter substrates succinyl (Suc)-LLVY-AMC, benzyloxy-carbonyl-
GGL-AMC, t-butyloxycarbonyl (Boc)-LRR-AMC, and benzyloxycarbonyl
(Z)-YVAD-AMC) (upper three panels) or labeled with Ada-[125I-
Tyr]Ahx3-Leu3-VS, followed by SDS-PAGE and autoradiography (lower
panel). b, EL-4ad cell viability was mostly independent of proteasomal
proteolysis. EL-4 (left panels) or EL-4ad (right panels) cells were left
untreated (upper panels) or were incubated with 50 M NLVS (middle
left panel) or 10 M (middle right panel) or 50 M (lower panels) Ada-
Ahx3-Leu3-VS for the indicated times. Live (E) and dead () cells were
counted by trypan blue exclusion.
FIG. 7. Increased in vivo tumorigenicity of cells with reduced
reliance on proteasomal proteolysis. Control EL-4 (open bars) and
EL-4ad (closed bars) cells were grafted at 104 to 106 cells into the right
flanks of syngeneic C57Bl/6 mice (a) or perforin/RAG-1/ mice (PKOB/
RAG/) (b). Frequency of tumor growth is displayed.
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shown). Thus, tumor cells may adapt and proliferate normally
even when proteasomal -subunit activity is almost absent.
Escape from in Vivo Immune Detection by Tumor Cells with
Reduced Reliance on Proteasomal Activity—In vivo tumors fre-
quently acquire mutations in genes encoding proteins of the
MHC class I-processing pathway, and these are believed to be
the result of immune selection (33). Therefore, we explored
whether an adapted phenotype similar to that of EL-4ad cells
was selected during growth in vivo. We inoculated control EL-4
and EL-4ad cells into syngeneic C57Bl/6 mice and observed
tumors in most mice inoculated with EL-4ad cells at both 106
and 104 cells/animal, whereas control EL-4 cells failed to grow
and produce tumors (Fig. 7a). The tumor-forming ability of
EL-4ad cells was dependent, at least in part, on escape from
immune recognition because both EL-4ad and control EL-4
cells formed tumors in mice with a deficiency of perforin and
RAG-1 (PKOB/RAG/) (Fig. 7a). Furthermore, after low dose
irradiation (400 rads) of the C57Bl/6 mice, commonly used to
reduce in vivo transplantation barriers (34), both control EL-4
and EL-4ad cells were able to grow after inoculation of 106
cells/animal, whereas only EL-4ad cells grew at 104 cells/ani-
mal (Fig. 7b). In conclusion, we have shown that the ability of
NLVS-adapted cells to proliferate independently of proteaso-
mal -subunit activities leads to reduced immune recognition
in vivo.
DISCUSSION
This study shows that tumor cells may avoid efficient pro-
duction of MHC class I ligands and hence immune recognition
by modulation of proteasomal activity. Pathways accessory to
proteasomal proteolysis can reduce the extent to which cells
depend on proteasomal activity. In our case, cells adapted to
growth in the presence of proteasomal inhibitors were unable
to maintain normal levels of MHC class I ligand production. In
addition, using the vinyl sulfone inhibitor Ada-Ahx3-Leu3-VS,
we showed that inhibition of all catalytic -subunit activities of
the proteasome (more efficiently than achieved with NLVS)
was compatible with continued cell growth of EL-4ad cells.
These results indicate that it is possible for mammalian cells to
partly escape from production of MHC class I ligands by aver-
sion to pathways of protein degradation involving proteases
other than the proteasome.
Although MHC class I processing is a rather inefficient proc-
ess overall, in which most (99%) of the cleaved peptides are
never displayed at the cell surface, it is an adequate method for
screening of the bulk of cellular protein content for the pres-
ence of foreign antigens (26). The steady-state level of MHC
class I at the surface of cells depends on both its transport and
removal from the cell surface (35), and transport of H-2Db is
substantially inhibited in EL-4ad cells. Despite this, the cell-
surface H-2Db (and also H-2Kb) levels detected by FACS are
almost normal, suggesting that the rate of decay at the cell
surface may be reduced when transport is slow (data not
shown). Earlier data on MHC class II transport in cathepsin
S/ mice have revealed a similar feature; and also in this case,
an absence of T cell detection is observed for certain antigens
(36, 37). In the course of an immune response, the proteolytic
specificity in antigen processing has profound influence on the
generation of MHC class I ligands, as illustrated by the IFN-
-dependent substitution of proteasomal -subunits (7). The
fact that pathways accessory to proteasomal proteolysis, such
as tripeptidyl-peptidase II, can contribute to maintaining pro-
teolysis when the proteasome is inhibited allows for mamma-
lian cells to alter the spectrum of cleavage fragments in the
cytosol more dramatically (10–13). This notion is supported by
the up-regulation of several deubiquitinating enzymes in EL-
4ad cells, observed otherwise in cells suffering from acute pro-
teasomal inhibition (24). USP14 is associated with the 19 S
regulatory complex, and its precise role in proteasomal prote-
olysis remains to be established. Other deubiquitinating en-
zymes are also up-regulated in EL-4ad cells, such as IsoT1 and
UCH-L1, which participate in the disassembly of free polyubiq-
uitin chains (38, 39). When the proteasome is blocked, the
removal of ubiquitin from ubiquitin-conjugated substrates may
be a crucial step to engage alternative proteolytic pathways.
Reduced expression of several components of the MHC class
I antigen-processing pathway is often observed in human tu-
mors. This includes down-regulation of the IFN--inducible
proteasomal -subunits (1i, 2i, and 5i) (40), important for
production of MHC class I ligands, as well as down-regulation
of other gene products involved in antigen processing (41–43).
Tumors may fail to produce certain immunodominant ligands
due to altered proteasomal specificity (40, 44). Our data show
that reduced reliance on proteasomal proteolysis biases cyto-
solic proteolysis to produce peptides that are less fit for MHC
class I assembly, thereby down-regulating the pool of potential
MHC class I-restricted epitopes. Such down-regulation is sta-
bly retained in rapidly proliferating cells and can be induced at
fairly high frequency (10). Furthermore, EL-4ad cells appear to
use this phenotype to avoid immunological rejection during the
formation of tumors in vivo. An EL-4ad-like phenotype may be
preferentially selected in tumors that are poorly antigenic, a
trait observed in many types of tumors. Interestingly, in Bur-
kitt’s lymphomas, the oncogene c-myc is known to induce down-
regulation of a number of components of the MHC class I-pro-
cessing pathway, including down-regulation of proteasomal
chymotryptic activity and up-regulation of tripeptidyl-pepti-
dase II, thus linking the deficiency in antigen processing di-
rectly to oncogene expression (45, 46). This study reveals a new
strategy for regulation of MHC class I processing: reduced
reliance on proteasomal activity to down-regulate generation of
MHC class I ligands
Acknowledgments—We thank members of the Ploegh laboratory for
support and discussions and Elisabeth Wolpert for CTL clone ln17. We
also thank Maria Masucci and Hans-Gustaf Ljunggren for discussions
and suggestions on the manuscript.
REFERENCES
1. Rock, K. L., and Goldberg A. L. (1999) Annu. Rev. Immunol. 17, 739–779
2. Stoltze, L., Schirle, M., Schwarz, G., Schroter, C., Thompson, M. W., Hersh,
L. B., Kalbacher, H., Stevanovic, S., Rammensee, H. G., and Schild H.
(2000) Nat. Immunol. 1, 413–418
3. Voges, D., Zwickl, P., and Baumeister, W. (1999) Annu. Rev. Biochem. 68,
1015–1068
4. Kisselev, A. F., Akopian, T. N., Woo, K. M., and Goldberg, A. L. (1999) J. Biol.
Chem. 274, 3363–3371
5. Tamura, N., Lottspeich, F., Baumeister, W., and Tamura, T. (1998) Cell 95,
637–648
6. Saric, T., Beninga, J., Graef, C. I., Akopian, T. N., Rock, K. L., and Goldberg,
A. L. (2001) J. Biol. Chem. 276, 36474–36481
7. Fruh, K., and Yang, Y. (1999) Curr. Opin. Immunol. 11, 76–81
8. Yewdell, J. W., and Bennink, J. R. (1999) Annu. Rev. Immunol. 17, 51–88
9. Chen, W., Norbury, C. C., Cho, Y., Yewdell, J. W., and Bennink, J. R. (2001) J.
Exp. Med. 193, 1319–1326
10. Glas, R., Bogyo, M., McMaster, J. S., Gaczynska, M., and Ploegh, H. L. (1998)
Nature 392, 618–622
11. Geier, E., Pfeifer, G., Wilm, M., Lucchiari-Hartz, M., Baumeister, W.,
Eichmann, K., and Niedermann, G. (1999) Science 283, 978–981
12. Wang, E. W., Kessler, B. M., Borodovsky, A., Cravatt, B. F., Bogyo, M., Ploegh,
H. L., and Glas, R. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 9990–9995
13. Tomkinson, B. (1999) Trends Biochem. Sci. 24, 355–359
14. Bogyo, M., McMaster, J. S., Gaczynska, M., Tortorella, D., Goldberg, A. L., and
Ploegh H. L. (1996) Proc. Natl. Acad. Sci. U. S. A. 94, 6629–6634
15. Fenteany, G., and Schreiber, S. L. (1998) J. Biol. Chem. 273, 8545–8548
16. Dantuma, N. P., Lindsten, K., Glas, R., Jellne, M., and Masucci, M. G. (2000)
Nat. Biotechnol. 18, 538–543
17. Kessler, B. M., Tortorella, D., Altun, M., Kisselev, A. F., Fiebiger, E., Hekking,
B. G., Ploegh, H. L., and Overkleeft, H. S. (2001) Chem. Biol. 8, 913–929
18. Machold, R. P., Andree, S., Van Kaer, L., Ljunggren, H.-G., and Ploegh, H. L.
(1995) J. Exp. Med. 181, 1111–1122
19. Benham, A. M., Gromme, M., and Neefjes, J. (1998) J. Immunol. 161, 83–89
20. Luckey, C. J., Marto, J. A., Partridge, M., Hall, E., White, F. M., Lippolis, J. D.,
Shabanowitz, J., Hunt, D. F., and Engelhard, V. H. (2001) J. Immunol. 167,
1212–1221
Cytosolic Proteolysis without MHC Class I Ligand Production10020
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
21. Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D.,
and Goldberg A. L. (1994) Cell 78, 761–771
22. Ljunggren, H.-G., Stam, N. J., Ohlen, C., Neefjes, J. J., Hoglund, P., Heemels,
M. T., Bastin, J., Schumacher, T. N., Townsend, A., Karre, K., and Ploegh,
H. L. (1990) Nature 346, 476–480
23. van Hall, T., van Bergen, J., van Veelen, P. A., Kraakman, M., Heukamp, L. C.,
Koning, F., Melief, C. J., Ossendorp, F., and Offringa, R. (2000) J. Immunol.
165, 869–877
24. Borodovsky, A., Kessler, B. M., Casagrande, R., Overkleeft, H. S., Wilkinson,
K. D., and Ploegh, H. L. (2001) EMBO J. 20, 5187–5196
25. Bogyo, M., Shin, S., McMaster, J. S., and Ploegh, H. L. (1998) Chem. Biol. 5,
307–320
26. Yewdell, J. W. (2001) Trends Cell Biol. 11, 294–297
27. Palmer, J. T., Rasnick, D., Klaus, J. L., and Bromme, D. (1995) J. Med. Chem.
38, 3193–3196
28. Heinemeyer, W., Kleinschmidt, J. A., Saidowsky, J., Escher, C., and Wolf,
D. H. (1991) EMBO J. 10, 555–562
29. Seufert, W., and Jentsch, S. (1992) EMBO J. 11, 3077–3080
30. Princiotta, M. F., Schubert, U., Chen, W., Bennink, J. R., Myung, J., Crews,
C. M., and Yewdell, J. W. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 513–518
31. Meng, L., Mohan, R., Kwok, B. H., Elofsson, M., Sin, N., and Crews, C. M.
(1999) Proc. Natl. Acad. Sci. U. S. A. 96, 10403–10408
32. Kisselev, A. F., Akopian, T. N., Castillo, V., and Goldberg, A L. (1999) Mol. Cell
4, 395–402
33. Pawelec, G., Heinzel, S., Kiessling, R., Muller, L., Ouyang, Q., and Zeuthen, J.
(2000) Crit. Rev. Oncog. 11, 97–133
34. Peng, L., Krauss, J. C., Plautz, G. E., Mukai, S., Shu, S., and Cohen, P. A.
(2000) J. Immunol. 165, 7116–7124
35. Su, R. C., and Miller, R. G. (2001) J. Immunol. 167, 4869–4877
36. Driessen, C., Bryant, R. A., Lennon-Dumenil, A. M., Villadangos, J. A., Bryant,
P. W., Shi, G. P., Chapman, H. A., and Ploegh, H. L. (1999) J. Cell Biol. 147,
775–790
37. Riese, R. J., Mitchell, R. N., Villadangos, J. A., Shi, G. P., Palmer, J. T., Karp,
E. R., De Sanctis, G. T., Ploegh, H. L., and Chapman, H. A. (1998) J. Clin.
Invest. 101, 2351–2363
38. Wilkinson, K. D., Tashayev, V. L., O’Connor, L. B., Larsen, C. N., Kasperek, E.,
and Pickart, C. M. (1995) Biochemistry 34, 14535–14546
39. Johnston, S. C., Larsen, C. N., Cook, W. J., Wilkinson, K. D., and Hill, C. P.
(1997) EMBO J. 16, 3787–3796
40. Frisan, T., Levitsky, V., Polack, A., and Masucci, M. G. (1998) J. Immunol. 160,
3281–3289
41. Delp, K., Momburg, F., Hilmes, C., Huber, C., and Seliger, B. (2000) Bone
Marrow Transplant. 25, Suppl. 2, 88–95
42. Algarra, I., Cabrera, T., and Garrido, F. (2000) Hum. Immunol. 61, 65–73
43. Wang, Z., Seliger, B., Mike, N., Momburg, F., Knuth, A., and Ferrone, S. (1998)
Cancer Res. 58, 2149–2157
44. Morel, S. et al. (2000) Immunity 12, 107–117
45. Gavioli, R., Frisan, T., Vertuani, S., Bornkamm, G. W., and Masucci, M. G.
(2001) Nat. Cell. Biol. 3, 283–288
46. Staege, M. S., Lee, S. P., Frisan, T., Mautner, J., Scholz, S., Pajic, A.,
Rickinson, A. B., Masucci, M. G., Polack, A., and Bornkamm, G. W. (2002)
Proc. Natl. Acad. Sci. U. S. A. 99, 4550–4555
Cytosolic Proteolysis without MHC Class I Ligand Production 10021
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Matthew Bogyo, Herman S. Overkleeft, Hidde Ploegh and Rickard Glas
Benedikt Kessler, Xu Hong, Jelena Petrovic, Anna Borodovsky, Nico P. Dantuma,
Histocompatibility Complex Class I Antigen Production
Pathways Accessory to Proteasomal Proteolysis Are Less Efficient in Major
doi: 10.1074/jbc.M211221200 originally published online December 16, 2002
2003, 278:10013-10021.J. Biol. Chem. 
  
 10.1074/jbc.M211221200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/278/12/10013.full.html#ref-list-1
This article cites 46 references, 20 of which can be accessed free at
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
